Demographic variable Number of patients Clinical response (%) Clinical remission (%) Endoscopic response (%) Endoscopic remission (%) Overall outcomes 120 73.3 66.7 64.2 55.0 Steroid naïve 61 82.0 73.8 70.5 60.7 Steroid dependent 59 64.4 59.3 57.6 49.2 In this cohort of 120 patients, at entry and one week post last GMA session, Rachmilewitz’s clinical activity index (CAI) was applied to assess disease activity.9 Likewise, Rachmilewitz’s endoscopic index (EI) was used to assess mucosal disease activity

Table 1: Rates of clinical remission, clinical response, endoscopic remission and endoscopic response in 120 patients with ulcerative colitis (UC) that received adsorptive granulocyte/monocyte apheresis (GMA) as a non-pharmacologic treatment intervention. At entry, the average clinical activity index (CAI) and endoscopic index (EI) were 12.6±1.71 (range 10-16), and 10.3±1.34 (range 7-12), respectively (n=120). CAI ≤4 was defined as clinical remission, while EI ≤3 was defined as endoscopic remission. Similarly, clinical response was judged as a decrease of 4 points in the CAI score relative to baseline, while a decrease of 3 points in the EI score was judged as endoscopic response.